It is also involved in modulating cell adhesion, which can affect cancer metastasis. Sacituzumab Govitecan is a well-known ADC that targets TROP2. It is approved for the treatment of triple-negative breast cancer (TNBC) and urothelial carcinoma. The ADC consists of a monoclonal antibody against TROP2 linked to SN-38, a potent topoisomerase I inhibitor that induces DNA damage and cell death. After binding to TROP2 on the surface of cancer cells, Sacituzumab Govitecan is internalized, and SN-38 is released inside the cell. SN-38 inhibits topoisomerase I, leading to DNA strand breaks, which ultimately triggers apoptosis in the cancer cells. Sacituzumab Govitecan has shown significant clinical activity in patients with heavily pretreated TNBC and metastatic urothelial carcinoma, demonstrating substantial improvements in progression-free survival (PFS) and overall survival (OS) compared to standard therapies. Besides the inter-group co-occurrences discussed above, we also identified concept pairs cooccurring within a group (therapeutic targets, cancer types, biomarkers, therapy types) shown in Supporting Information S2-S5.